Nima serves as the Chief Executive Officer at Latigo Biotherapeutics, bringing more than two decades of leadership experience in the biopharmaceutical industry. Known for his strong track record in fundraising and initial public offerings (IPOs), Nima is focused on positioning Latigo for rapid growth and success.

Nima’s career is marked by his notable tenure as CEO of Kinnate Biopharma, where he led the company through its successful IPO of $270 million and eventual sale to Xoma Corporation in April 2024. During his time at Kinnate, he built an organization that advanced three precision oncology compounds into clinical development.

Prior to Kinnate, Nima spent seven years at PaxVax, serving as president and CEO. At PaxVax, he led a team of 250 people through several successful financings, the licensure from the U.S. Food and Drug Administration of Vaxchora, the grant of a Priority Review Voucher from the FDA and the acquisition of several programs from Johnson & Johnson. His strategic leadership resulted in several commercial product launches and the eventual sale of PaxVax to Emergent BioSolutions, generating nearly $500 million for shareholders between the two transactions.

Nima’s earlier career includes significant roles at Novartis AG, DoubleTwist, and the Boston Consulting Group. He is a director of Keros Therapeutics and a founding board member of the Coalition for Epidemic Preparedness Innovations. He holds an MBA from Harvard Business School and a BA in human biology with honors from Stanford University.